News | May 16, 2025
JB Pharma records revenue growth of 10% to Rs. 949 crore in Q4 FY25
Net Profit increased by 15% to Rs. 146 crores in Q4 FY25 and 19% to Rs. 660 crores in FY25
Net Profit increased by 15% to Rs. 146 crores in Q4 FY25 and 19% to Rs. 660 crores in FY25
EBITDA before special items decreases to €4.08 billion (7.4%)
Scores highest PAT of Rs. 118 crore in FY25
Delivers robust earnings performance, successfully navigating a dynamic environment
Planned acquisition will strengthen the presence of Merck Healthcare in the United States and expand reach of SpringWorks’ therapeutic innovations to more patients with rare tumors worldwide
Bayer expects 2025 to be the most difficult year of its turnaround
Profit after Taxes registered strong growth of 22% to Rs. 162 crores versus Rs. 134 crores in Q3 FY24
The group reported Q3FY25 operating revenue of Rs 3,821 crore, driven by sustained double-digit growth of 14 per cent in biosimilars
The company said it voluntarily paused production at the Gagillapur plant in September 2024 for risk assessment on account of the USFDA observations
In 2023, Endox had revenues of approximately SEK 65 million
Subscribe To Our Newsletter & Stay Updated
